LBDA

Nelotanserin for Potential Treatment of REM Sleep Behavior Disorder in DLB

What is this study about?

This trial is testing an experimental drug (called nelotanserin) to determine its effectiveness in treating REM sleep behavior disorder in people with dementia with Lewy bodies (DLB).

What is involved?

The study begins with a “double-blind, placebo controlled” phase, meaning neither the re-searcher nor the person in the trial will know who is getting the study drug or a placebo.

Then, the study will continue with an open-label extension, in which all participants will receive nelotanserin.

Each participant will attend an initial screening visit plus 4 additional study visits over the course of approximately 10 weeks. Transportation assistance to and from study visits may be available.

Who can participate?

An individual may be able to take part in the trial if he/she:

  • Is between the ages of 50 and 85
  • Has been diagnosed with dementia with Lewy bodies (DLB)
  • Experiences frequent REM sleep behavior episodes (physically acting out dreams during sleep)
Find a Study Site
 

Study Sponsor:

Axovant Sciences, Ltd.

Still have questions?

For more information about this clinical trial, please contact (919) 425-0709.